Cited 0 times in
Tumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, B | - |
dc.contributor.author | Hwang, Y | - |
dc.contributor.author | Kwon, HJ | - |
dc.contributor.author | Lee, ES | - |
dc.contributor.author | Park, Kc | - |
dc.contributor.author | Bang, D | - |
dc.contributor.author | Lee, S | - |
dc.contributor.author | Sohn, S | - |
dc.date.accessioned | 2011-01-13T02:09:58Z | - |
dc.date.available | 2011-01-13T02:09:58Z | - |
dc.date.issued | 2008 | - |
dc.identifier.issn | 0923-1811 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/1122 | - |
dc.description.abstract | BACKGROUND: Anti-TNFalpha antibodies have been used for treating inflammation in patients. But, more effective and safer drugs need to be developed for improved future therapeutic use.
OBJECTIVES: To inhibit the expression of TNFalpha, we used small interfering RNAs (siRNAs) to reduce over expression of TNFalpha in vitro in cell cultures and in an in vivo Behcet's disease-like (BD) mouse model for amelioration of chronic inflammation. METHODS: TNFalpha siRNA was injected intraperitoneally twice with a 1-week interval. To compare the efficacy of TNFalpha siRNA versus an anti-TNFalpha antibody, Infliximab and Etanercept were administered to symptomatic mice with inflamed tissue. RESULTS: Intraperitoneal delivery of TNFalpha siRNA effectively decreased BD symptoms in 18 of 32 cases (56.3%). Scrambled siRNA treatment decreased BD symptoms in 2 of 19 cases (10.5%). Infliximab was effective in 11 of 27 cases (40.7%) and Etanercept was also effective in 9 of 25 cases (36.0%) at the end of the second week after treatment. TNFalpha siRNA reduced serum levels of TNFalpha (1.57 +/- 0.43pg/ml), compared to levels in mice not injected (84.02 +/- 24.59pg/ml) (p<0.01) or scramble injected (118.89 +/- 20.08pg/ml) (p<0.01). After single injection of TNFalpha siRNA, improvement of BD symptoms showed at 9 +/- 7th day on an average, contrary, in Infliximab injected group, improvement was apparent at 15 +/- 4th day after injection (p<0.05). CONCLUSION: We show that siRNAs can be employed to inhibit cytokine gene expression in an in vivo disease mouse model. This inhibition may, therefore, be attributed to the improvement of inflammatory symptoms. | - |
dc.language.iso | en | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Anti-Inflammatory Agents | - |
dc.subject.MESH | Antibodies, Monoclonal | - |
dc.subject.MESH | Behcet Syndrome | - |
dc.subject.MESH | Cells, Cultured | - |
dc.subject.MESH | Cytokines | - |
dc.subject.MESH | Disease Models, Animal | - |
dc.subject.MESH | Immunoglobulin G | - |
dc.subject.MESH | Lipopolysaccharides | - |
dc.subject.MESH | Macrophages | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Mice | - |
dc.subject.MESH | Mice, Inbred ICR | - |
dc.subject.MESH | RNA, Small Interfering | - |
dc.subject.MESH | Receptors, Tumor Necrosis Factor | - |
dc.subject.MESH | Simplexvirus | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Tumor Necrosis Factor-alpha | - |
dc.title | Tumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model. | - |
dc.type | Article | - |
dc.identifier.pmid | 18585901 | - |
dc.identifier.url | http://linkinghub.elsevier.com/retrieve/pii/S0923-1811(08)00154-0 | - |
dc.contributor.affiliatedAuthor | 이, 은소 | - |
dc.contributor.affiliatedAuthor | 손, 성향 | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.1016/j.jdermsci.2008.05.001 | - |
dc.citation.title | Journal of dermatological science | - |
dc.citation.volume | 52 | - |
dc.citation.number | 2 | - |
dc.citation.date | 2008 | - |
dc.citation.startPage | 87 | - |
dc.citation.endPage | 97 | - |
dc.identifier.bibliographicCitation | Journal of dermatological science, 52(2). : 87-97, 2008 | - |
dc.identifier.eissn | 1873-569X | - |
dc.relation.journalid | J009231811 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.